Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.

Glatthar R, Stojanovic A, Troxler T, Mattes H, Möbitz H, Beerli R, Blanz J, Gassmann E, Drückes P, Fendrich G, Gutmann S, Martiny-Baron G, Spence F, Hornfeld J, Peel JE, Sparrer H.

J Med Chem. 2016 Aug 25;59(16):7544-60. doi: 10.1021/acs.jmedchem.6b00598. Epub 2016 Aug 17.

PMID:
27502541
2.

A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis.

Bold G, Schnell C, Furet P, McSheehy P, Brüggen J, Mestan J, Manley PW, Drückes P, Burglin M, Dürler U, Loretan J, Reuter R, Wartmann M, Theuer A, Bauer-Probst B, Martiny-Baron G, Allegrini P, Goepfert A, Wood J, Littlewood-Evans A.

J Med Chem. 2016 Jan 14;59(1):132-46. doi: 10.1021/acs.jmedchem.5b01582. Epub 2015 Dec 21.

PMID:
26629594
3.

Podocyte EphB4 signaling helps recovery from glomerular injury.

Wnuk M, Hlushchuk R, Janot M, Tuffin G, Martiny-Baron G, Holzer P, Imbach-Weese P, Djonov V, Huynh-Do U.

Kidney Int. 2012 Jun;81(12):1212-25. doi: 10.1038/ki.2012.17. Epub 2012 Mar 7.

4.

Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.

Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G, Confalonieri S, Quarto M, Hu G, Balwierz PJ, Pachkov M, Elledge SJ, van Nimwegen E, Stadler MB, Bentires-Alj M.

Nat Med. 2012 Mar 4;18(4):529-37. doi: 10.1038/nm.2645.

PMID:
22388088
5.

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.

Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chène P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, García-Echeverría C, Sellers WR, Voliva CF.

Mol Cancer Ther. 2012 Feb;11(2):317-28. doi: 10.1158/1535-7163.MCT-11-0474. Epub 2011 Dec 21.

6.

Targeting cancer with small-molecular-weight kinase inhibitors.

Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G.

Methods Mol Biol. 2012;795:1-34. doi: 10.1007/978-1-61779-337-0_1. Review.

PMID:
21960212
7.

Characterization of kinase inhibitors using reverse phase protein arrays.

Martiny-Baron G, Haasen D, D'Dorazio D, Voshol J, Fabbro D.

Methods Mol Biol. 2011;785:79-107. doi: 10.1007/978-1-61779-286-1_7.

PMID:
21901595
8.

The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.

Martiny-Baron G, Holzer P, Billy E, Schnell C, Brueggen J, Ferretti M, Schmiedeberg N, Wood JM, Furet P, Imbach P.

Angiogenesis. 2010 Sep;13(3):259-67. doi: 10.1007/s10456-010-9183-z. Epub 2010 Aug 29.

9.

Extended kinase profile and properties of the protein kinase inhibitor nilotinib.

Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, Mestan J, Trappe J, Wartmann M, Fabbro D.

Biochim Biophys Acta. 2010 Mar;1804(3):445-53. doi: 10.1016/j.bbapap.2009.11.008. Epub 2009 Nov 14.

PMID:
19922818
10.

Inhibition of angiogenesis in lipodermatosclerosis: implication for venous ulcer formation.

Herouy Y, Kreis S, Mueller T, Duerk T, Martiny-Baron G, Reusch P, May F, Idzko M, Norgauer Y.

Int J Mol Med. 2009 Nov;24(5):645-51.

PMID:
19787198
11.

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17.

12.

Classical PKC isoforms in cancer.

Martiny-Baron G, Fabbro D.

Pharmacol Res. 2007 Jun;55(6):477-86. Epub 2007 Apr 21. Review.

PMID:
17548205
13.

Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity.

Chrencik JE, Brooun A, Recht MI, Kraus ML, Koolpe M, Kolatkar AR, Bruce RH, Martiny-Baron G, Widmer H, Pasquale EB, Kuhn P.

Structure. 2006 Feb;14(2):321-30.

14.

Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organization.

Weber CC, Cai H, Ehrbar M, Kubota H, Martiny-Baron G, Weber W, Djonov V, Weber E, Mallik AS, Fussenegger M, Frei K, Hubbell JA, Zisch AH.

J Biol Chem. 2005 Jun 10;280(23):22445-53. Epub 2005 Mar 21.

15.

Inhibition of tumor growth and angiogenesis by soluble EphB4.

Martiny-Baron G, Korff T, Schaffner F, Esser N, Eggstein S, Marmé D, Augustin HG.

Neoplasia. 2004 May-Jun;6(3):248-57.

16.

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.

García-Echeverría C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F.

Cancer Cell. 2004 Mar;5(3):231-9.

17.

Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth.

Ehrbar M, Djonov VG, Schnell C, Tschanz SA, Martiny-Baron G, Schenk U, Wood J, Burri PH, Hubbell JA, Zisch AH.

Circ Res. 2004 Apr 30;94(8):1124-32. Epub 2004 Mar 25.

PMID:
15044320
18.

Therapies directed at vascular endothelial growth factor.

Manley PW, Martiny-Baron G, Schlaeppi JM, Wood JM.

Expert Opin Investig Drugs. 2002 Dec;11(12):1715-36. Review.

PMID:
12457433
19.

Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats.

Fiedler U, Krissl T, Koidl S, Weiss C, Koblizek T, Deutsch U, Martiny-Baron G, Marmé D, Augustin HG.

J Biol Chem. 2003 Jan 17;278(3):1721-7. Epub 2002 Nov 9.

20.

Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors.

Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G, Marmé D.

Angiogenesis. 2001;4(2):143-54.

PMID:
11806246
21.

Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood.

Reusch P, Barleon B, Weindel K, Martiny-Baron G, Gödde A, Siemeister G, Marmé D.

Angiogenesis. 2001;4(2):123-31.

PMID:
11806244
23.

Active interaction of human A375 melanoma cells with the lymphatics in vivo.

Papoutsi M, Siemeister G, Weindel K, Tomarev SI, Kurz H, Schächtele C, Martiny-Baron G, Christ B, Marmé D, Wilting J.

Histochem Cell Biol. 2000 Nov;114(5):373-85.

PMID:
11151407
24.

Donor stromal cells from human blood engraft in NOD/SCID mice.

Goan SR, Junghahn I, Wissler M, Becker M, Aumann J, Just U, Martiny-Baron G, Fichtner I, Henschler R.

Blood. 2000 Dec 1;96(12):3971-8.

PMID:
11090086
25.

Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.

Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Müller M, Wood J, Martiny-Baron G, Unger C, Marmé D.

Cancer Res. 2000 Sep 1;60(17):4819-24.

26.

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis

Bold G, Altmann KH, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Bruggen J, Buchdunger E, Cozens R, Ferrari S, Furet P, Hofmann F, Martiny-Baron G, Mestan J, Rosel J, Sills M, Stover D, Acemoglu F, Boss E, Emmenegger R, Lasser L, Masso E, Roth R, Schlachter C, Vetterli W.

J Med Chem. 2000 Aug 10;43(16):3200. No abstract available.

PMID:
10956229
27.

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

Bold G, Altmann KH, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Brüggen J, Buchdunger E, Cozens R, Ferrari S, Furet P, Hofmann F, Martiny-Baron G, Mestan J, Rösel J, Sills M, Stover D, Acemoglu F, Boss E, Emmenegger R, Lässer L, Masso E, Roth R, Schlachter C, Vetterli W.

J Med Chem. 2000 Jun 15;43(12):2310-23. Erratum in: J Med Chem 2000 Aug 10;43(16):3200.

PMID:
10882357
28.

Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro.

Benzinger P, Martiny-Baron G, Reusch P, Siemeister G, Kley JT, Marmé D, Unger C, Massing U.

Biochim Biophys Acta. 2000 Jun 1;1466(1-2):71-8.

29.

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F.

Cancer Res. 2000 Apr 15;60(8):2178-89.

30.
31.

The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities.

Siemeister G, Martiny-Baron G, Marmé D.

Cancer Metastasis Rev. 1998 Jun;17(2):241-8. Review. No abstract available.

PMID:
9770121
32.
33.

An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells.

Siemeister G, Schirner M, Reusch P, Barleon B, Marmé D, Martiny-Baron G.

Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4625-9.

34.
35.

Novel antibodies directed against the extracellular domain of the human VEGF-receptor type II.

Menrad A, Thierauch KH, Martiny-Baron G, Siemeister G, Schirner M, Schneider MR.

Hybridoma. 1997 Oct;16(5):465-71.

PMID:
9388030
36.

Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1.

Barleon B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeister G, Marmé D, Martiny-Baron G.

J Biol Chem. 1997 Apr 18;272(16):10382-8.

37.

Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor-tissue homogenates.

Schlaeppi JM, Eppenberger U, Martiny-Baron G, Küng W.

Clin Chem. 1996 Nov;42(11):1777-84.

PMID:
8906076
38.

VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane.

Wilting J, Birkenhäger R, Eichmann A, Kurz H, Martiny-Baron G, Marmé D, McCarthy JE, Christ B, Weich HA.

Dev Biol. 1996 May 25;176(1):76-85.

39.

Expression of biologically active isoforms of the tumor angiogenesis factor VEGF in Escherichia coli.

Siemeister G, Schnurr B, Mohrs K, Schächtele C, Marmé D, Martiny-Baron G.

Biochem Biophys Res Commun. 1996 May 15;222(2):249-55.

PMID:
8670191
40.

Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.

Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marmé D.

Cancer Res. 1996 May 15;56(10):2299-301.

41.

VEGF-mediated tumour angiogenesis: a new target for cancer therapy.

Martiny-Baron G, Marmé D.

Curr Opin Biotechnol. 1995 Dec;6(6):675-80. Review.

PMID:
8527839
42.

Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis.

Kolch W, Martiny-Baron G, Kieser A, Marmé D.

Breast Cancer Res Treat. 1995;36(2):139-55. Review.

PMID:
8534863
43.

Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976.

Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, Marmé D, Schächtele C.

J Biol Chem. 1993 May 5;268(13):9194-7.

44.

Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity.

Mischak H, Goodnight JA, Kolch W, Martiny-Baron G, Schaechtle C, Kazanietz MG, Blumberg PM, Pierce JH, Mushinski JF.

J Biol Chem. 1993 Mar 25;268(9):6090-6.

45.

Proton transport and phosphorylation of tonoplast polypeptides from zucchini are stimulated by the phospholipid platelet-activating factor.

Martiny-Baron G, Manolson MF, Poole RJ, Hecker D, Scherer GF.

Plant Physiol. 1992 Aug;99(4):1635-41.

46.

Molecular aspects of the neuronal noradrenaline transporter.

Bönisch H, Paulus G, Martiny-Baron G, Lingen B, Coppeneur D.

J Neural Transm Suppl. 1991;34:11-7.

PMID:
1726219
47.

Biochemical characterization and purification of the neuronal sodium-dependent noradrenaline transporter.

Bönisch H, Martiny-Baron G, Blum B, Michael-Hepp J.

J Neural Transm Suppl. 1990;32:413-9.

PMID:
2089105
48.

Phospholipid-stimulated protein kinase in plants.

Martiny-Baron G, Scherer GF.

J Biol Chem. 1989 Oct 25;264(30):18052-9.

49.

A plant protein kinase and plant microsomal H(+) transport are stimulated by the ether phospholipid platelet-activating factor.

Martiny-Baron G, Scherer GF.

Plant Cell Rep. 1988 Dec;7(7):579-82. doi: 10.1007/BF00272762.

PMID:
24240422
50.

Supplemental Content

Loading ...
Support Center